文件显示 ， 2022年 ， 联讯仪器 净 利 润 为 -3788.88 万 元 ， 2022 年 7月 公 司 股 改 前 决 议 向全体股东按照出资比例 现金分红2106.41万元 。 对此 ， 科创板要求说明2 0 2 2年公司分红的背景原因 ， 所履行的决策程序及其合规性 。 回复文件表示 ， 联讯仪器于2 0 2 2年1 0月完成了股份制改制 ， 股改基准日为2 0 2 2年7月3 1日 。 为解决部 分 股 东 股 改 纳 税 等资金需求的问题 ， 经2 0 2 2年7月2 5日公司股东会审议通过 ， 决议以截至2 0 2 2年6月3 0日的未分配利润向全体在册股东按照出资比例进行现金分红 ， 合 计 分配2 1 0 6 . 4 1万元(含税) ， 并于当月实施完毕 。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日 ， 苏州联讯仪器股份 有限公司 （ 以下简称 ： 联讯仪器 ） 披露科创板IPO问询回复文件 ， 保荐机构中信证券 ， 保荐代表人赵耀 、 孟硕 ， 会计师事务所为容诚会计师事务所 。 | 版 权 ： 本 ...

Core Viewpoint - The company, China Electronics Technology Group Corporation Blue Sky Technology Co., Ltd. (referred to as "Electric Blue Sky"), is undergoing a second round of inquiry for its IPO on the Sci-Tech Innovation Board, aiming to raise 1.5 billion yuan for the industrialization of aerospace power systems [1] Group 1: Company Overview - Electric Blue Sky specializes in the research, production, sales, and service of electric energy products and systems, offering comprehensive solutions for power generation, energy storage, control, and system integration [1] - The company's products have a wide application range, covering from deep sea (1 kilometer underwater) to deep space (2.25 million kilometers from Earth) [1] Group 2: IPO Details - The IPO application was accepted on June 28, 2025, and entered the inquiry phase on July 20 of the same year [1] - The company plans to raise 1.5 billion yuan, which will be allocated to the first phase of the aerospace power system industrialization project after deducting issuance costs [1] Group 3: Inquiry Focus - In the second round of inquiry, Electric Blue Sky faced questions regarding its aerospace power business, revenue and gross margin, accounts receivable, and notes receivable [1]

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. (Tainuo Maibo) has become a market focus as the first company to apply for listing under the fifth set of standards of the Sci-Tech Innovation Board after its restart, but its actual sales performance of its core product, Staitouta Monoclonal Antibody, has fallen short of expectations, completing only 47.6% of projected sales [1][2]. Company Overview - Tainuo Maibo was established in 2015 and focuses on innovative biopharmaceuticals aimed at global markets, particularly in blood product alternatives [2]. - The company's core product, Staitouta Monoclonal Antibody (trade name: Xintuituo), was approved for sale in China in February, while another key product, TNM001, is undergoing Phase III clinical trials [2]. Sales Performance - From March to September, the self-operated team expected to sell 56,800 bottles of Staitouta, but only sold 43,500 bottles, achieving 76.67% of the target. The external promotion team expected to sell 40,100 bottles but only sold 2,600, achieving 6.42% of the target. Overall, the total expected sales were 96,900 bottles, with actual sales at 46,100 bottles, resulting in a completion rate of 47.6% [2][3]. Reasons for Sales Shortfall - The company attributed the shortfall in sales to underestimating the time required for non-medical insurance drug hospital access and the high pricing of the drug at its current stage. Additionally, the external promotion team needed more time to understand and convey the product's advantages [3]. Sales Team and Expenses - Despite the underperformance in sales, Tainuo Maibo has a high sales expense, with projected sales expenses of 3.89 million, 12.42 million, and 35.11 million for 2022, 2023, and 2024 respectively. In Q1 of this year, sales expenses reached 24 million [4]. - As of the end of Q1, the company had 350 sales personnel, representing 45.63% of its total workforce of 767 employees, indicating a significant investment in building a sales team [4]. Financial Health - The company's debt-to-asset ratio has significantly increased, with figures of 16.54%, 28.19%, 58.96%, and 56.5% for 2022, 2023, and Q1 of this year respectively. This ratio is higher than the average of comparable companies [5][6]. - The increase in the debt-to-asset ratio is attributed to increased spending on drug research and commercialization team building, leading to a decrease in cash reserves [6][7]. Future Outlook - Tainuo Maibo believes that despite the rising debt-to-asset ratio, it remains within the overall range of comparable companies and does not face significant repayment pressure. The company anticipates that cash inflows will increase with the sales growth of Staitouta and the upcoming launch of TNM001 [7].

Core Viewpoint - Rongxin Huike Electric Co., Ltd. is attempting to go public on the Sci-Tech Innovation Board (STAR Market) again after a previous unsuccessful attempt, with a planned fundraising of 977 million yuan [1] Company Overview - Rongxin Huike is a high-tech enterprise specializing in the research, manufacturing, sales, and service of core equipment for new power systems, providing flexible transmission complete equipment and high-power converters [1] Financial Performance - The projected operating revenues for Rongxin Huike from 2022 to the first half of 2025 are approximately 1.942 billion yuan, 233 million yuan, 508 million yuan, and 234 million yuan respectively [1] - The corresponding net profits attributable to the company are expected to be around 182 million yuan, -56.28 million yuan, 35.42 million yuan, and -5.37 million yuan for the same periods [1] Fundraising Purpose - The company aims to use the raised funds for the research and industrialization of offshore wind power transmission complete devices and key technologies, the development of green low-carbon flexible power core equipment, the establishment of a research/testing center, and to supplement working capital [1] Previous IPO Attempt - This is the second attempt by Rongxin Huike to list on the STAR Market, having previously received acceptance for its IPO application in December 2021, which was later withdrawn in June 2022 [1]

Core Viewpoint - Chengdu Leap Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, focusing on advanced precision laser technology and semiconductor innovation processes, with significant growth in revenue and net profit during the reporting period [1][9] Revenue and Profit Growth - The company demonstrated strong growth, with revenue increasing from 74.15 million yuan in 2022 to 281 million yuan in 2024, achieving a compound annual growth rate of 96.25% [2] - Net profit turned from a loss of 9.38 million yuan in 2022 to a profit of 54.91 million yuan in 2024, with a slight profit of 683,200 yuan in Q1 2025 [2] R&D Investment Analysis - R&D expenses increased during the reporting period, with amounts of 15.28 million yuan, 23.95 million yuan, 58.74 million yuan, and 10.50 million yuan respectively [2] - The proportion of R&D expenses to revenue showed significant volatility, with figures of 20.61%, 12.56%, 20.9%, and 28.66% [3] - A notable increase in R&D expenses in 2024 by 145.23% was driven by external validation services and fixed asset investments, raising concerns about the sustainability of core technology development [3] Profit Quality and Asset Efficiency - Despite rapid profit growth, the company exhibited weaknesses in profit quality and asset operational efficiency, with negative cash flow from operating activities in most periods except for 2024 [4] - The net cash flow in 2024 was primarily due to an increase in operating payables, indicating a weak ability to convert revenue into cash [4] Accounts Receivable and Inventory Management - Accounts receivable increased significantly, with balances of 40.73 million yuan, 50.57 million yuan, 118 million yuan, and 117 million yuan, reflecting a rising proportion of accounts receivable to revenue [5] - Inventory value rose from 90.44 million yuan in 2022 to 226 million yuan in Q1 2025, with an increasing provision for inventory impairment, indicating potential issues in inventory management [5] Expense Control and Compliance - Management expenses increased from 14.71 million yuan in 2022 to 28.09 million yuan in 2024, with fluctuations in the proportion of revenue [6] - The company has a history of non-compliant dividend distributions, which raises concerns about internal governance and financial accounting practices [7] Financial Structure and Debt Pressure - The company’s financial structure shows a significant increase in liabilities, with a debt ratio rising from 28.91% in 2023 to 49.12% in Q1 2025 [8] - The company faces increased financial risk due to a declining short-term solvency ratio and a heavy reliance on long-term debt [8] Overall Assessment - Leap Technology has achieved rapid revenue and profit growth in the high-end semiconductor equipment sector, but faces scrutiny regarding profitability quality, asset management efficiency, and financial compliance as it seeks to meet the listing requirements of the Sci-Tech Innovation Board [9]

另外，上市委要求公司结合报告期内收入整体变动、季节性波动、验收标准、内控执行、验收期及回款 等情况，说明收入确认是否与同行业可比公司相一致，收入确认时点是否准确。 据了解，易思维专注于汽车制造机器视觉设备的研发、生产及销售，公司科创板IPO于2025年6月5日获 得受理，当年6月27日进入问询阶段。本次冲击上市，公司拟募集资金约12.14亿元，扣除发行费用后拟 用于机器视觉产品产业化基地项目、机器视觉研发中心项目、补充流动资金。 在上市委会议现场，上市委要求易思维结合汽车整车制造机器视觉领域市场空间、技术壁垒、竞争格局 及未来趋势、下游客户需求及开拓情况、报告期内产销量及收入变动等，说明未来业绩是否存在大幅波 动风险。 北京商报讯（记者 马换换 王蔓蕾）11月21日，上交所官网显示，易思维（杭州）科技股份有限公司 （以下简称"易思维"）科创板IPO当日上会获得通过。 ...

Group 1 - The core viewpoint of the article is that Shenzhen Hengyunchang Vacuum Technology Co., Ltd. has submitted its IPO registration to the Sci-Tech Innovation Board after a five-month process, with a fundraising target of 1.55 billion yuan for various projects [3] - The company was established in 2013 with a registered capital of 50.77 million yuan and is a core component supplier for semiconductor equipment [3] - The underwriter for the IPO is CITIC Securities, with representatives Wang Chunnan and Cao Yang, and the accounting firm is Tianjian Accounting Firm [3] Group 2 - The company is facing inquiries from the listing committee regarding its growth potential and the adequacy of disclosures related to performance volatility risks, as well as its independence and stability in business relationships with major clients [3] - From 2022 to 2024, the company's projected operating revenues are 158 million yuan, 325 million yuan, and 541 million yuan, respectively, with net profits attributable to shareholders of 19.81 million yuan, 69.24 million yuan, and 131 million yuan after deducting non-recurring gains and losses [4] - The gross profit margins for the main business are expected to be 41.65%, 46.11%, and 48.71% for the years 2022, 2023, and 2024, respectively [4]

Core Viewpoint - Shenzhen Hengyun Chang Vacuum Technology Co., Ltd. has successfully passed the IPO review for the Sci-Tech Innovation Board and has submitted its registration shortly thereafter [1] Company Overview - Hengyun Chang specializes in the research, production, sales, and technical services of core components for semiconductor equipment, including plasma radio frequency power systems, plasma excitation devices, and plasma DC power supplies [1] - The company also provides overall solutions for core components related to plasma processes by integrating vacuum acquisition and fluid control technologies [1] IPO Details - The IPO application was accepted on June 13, 2025, entered the inquiry stage on July 6, and was approved on November 14, with registration submitted on the same evening [1] - Hengyun Chang aims to raise approximately 1.469 billion yuan through this IPO [1]

Core Viewpoint - Shenzhen Hengyun Chang Vacuum Technology Co., Ltd. (Hengyun Chang) is facing significant challenges ahead of its IPO on the Sci-Tech Innovation Board, with a notable decline in performance and increasing reliance on a major customer, which raises concerns about its long-term profitability and stability [1][2][3]. Financial Performance - In 2024, Hengyun Chang achieved a revenue of 541 million yuan, a year-on-year increase of 66.26%, and a net profit of 131 million yuan, up 88.58% year-on-year [1]. - However, in the first half of 2025, the company reported a revenue of 304 million yuan, a mere 4.06% increase year-on-year, and a net profit of approximately 69.35 million yuan, down 11.99% year-on-year [1]. - The third quarter of 2025 saw a further decline, with revenue dropping by 27.29% year-on-year and net profit plummeting by 46.16% [1]. Order Backlog and Customer Dependency - The company's order backlog has been shrinking, with only 120 million yuan in hand orders in the first half of 2025, down from 260 million yuan in 2023 and 155 million yuan in 2024 [1]. - Hengyun Chang is heavily dependent on its largest customer, Tuojing Technology, which accounted for 63.13% of its revenue in 2024 and 62.06% in the first half of 2025 [2][3]. Accounts Receivable and Credit Policy - The accounts receivable balance surged from approximately 1.99 million yuan in 2022 to 13.02 million yuan in the first half of 2025, with the proportion of accounts receivable to revenue increasing from 12.63% to 42.83% [3][4]. - In the first half of 2025, accounts receivable from Tuojing Technology represented 58.82% of total accounts receivable, indicating a significant increase of 150.55% compared to the previous year [3][4]. - Hengyun Chang adjusted its credit policy from a 30-day payment term to a 60-day term, which has led to a notable increase in accounts receivable and a decrease in accounts receivable turnover rate from 7.81 times per year to 6.19 times per year [4][5]. Market Concerns - The significant fluctuations in Hengyun Chang's performance have raised concerns about its long-term profitability, especially given the volatility in the semiconductor industry [2][4]. - The company has denied any intention to relax credit policies to boost sales, but the correlation between the credit policy adjustment and the increase in accounts receivable raises questions about revenue quality and cash flow efficiency [4][5].

Core Viewpoint - Shenzhen Hengyun Chang Vacuum Technology Co., Ltd. has successfully passed the IPO review for the Sci-Tech Innovation Board, aiming to raise approximately 1.469 billion yuan [1] Company Overview - Hengyun Chang is a core component supplier for semiconductor equipment, focusing on the research, production, sales, and technical services of plasma RF power systems, plasma excitation devices, plasma DC power supplies, and various accessories [1] - The company provides comprehensive solutions for core components surrounding plasma technology, including the introduction of vacuum acquisition and fluid control components [1] IPO Details - The IPO application was accepted on June 13, 2025, and entered the inquiry phase on July 6 of the same year [1] - The company plans to raise around 1.469 billion yuan through this IPO [1] Market and Client Considerations - The listing committee has requested Hengyun Chang to explain its growth potential in relation to market demand, major client revenue proportions, and client development [1] - The committee also emphasized the need for the company to disclose risks related to performance fluctuations and the impact of client concentration on its independence and sustainability of cooperation with major clients [1]